@ATK Damn, now lending interest rates climbing, hope you can tahan until year end. Yes I think UK will be first, the rest will fall in line like domino. Just need 1 state/country to approve.
How is Genting B valuing its 20% exposure in investment in Taurx? Is it at book cost or mark to market? Surely it can’t be mark to market as Genting would have much higher valuation!
Genting we all know is undervalued ……however the market is bad and Malaysian market has been very bad for some time. Let’s see if the results are much better and if management have been able control costs.
人要敢于幻想....敢于梦想,最后才有希望...实现梦想。if Genting were to achieve earnings of 400 millions in the upcoming quarterly report, it could potentially rise to 6.00..。 go go Genting
Some info. about Taurx from google: Where is TauRx located? Singapore, TauRx is incorporated in Singapore with primary research and operations in Aberdeen, Scotland.
Who is the CEO of TauRx? Professor Claude Wischik For three decades, Professor Claude Wischik, co-founder and CEO of TauRx, has led a scientific research team dedicated to find an effective treatment for neurodegenerative disease. Professor Wischik is a board-certified psychiatrist and holder of a Chair in Mental Health at the University of Aberdeen.
TauRx’s deliver Alzheimer’s disease therapy results 17th July 2023 Company’s hydromethylthionine mesylate therapy reduced neurodegeneration during pivotal trial
TauRx Pharmaceuticals – a company focused on Alzheimer’s disease (AD) research – has announced results from its pivotal phase 3 LUCIDITY trial. . . Henrik Zetterberg, professor of neurochemistry at UCL Queen Square Institute of Neurology, concluded: “NfL is a well studied biomarker with wide applicability to different neurological disorders, including AD.
“Clinical practice has been waiting decades to uncover meaningful advancements to address unmet needs of people with AD. These new results further support the importance of NfL as an AD biomarker both for diagnosis and measurement of treatment effect.”
TauRx now intends to submit the HMTM results from LUCIDITY and previous trials for regulatory approval in the US, UK and several other territories.
The "private value" of USD200-300 has been mentioned for many years. TauRx is a 30 year old "company".
The news about submitting for regulatory approval is old news.
The trouble with Private value is that it's really worth nothing until someone else buys. Until then, all you have is speculations. And speculations that has lasted years and years. The wait can be long. The payoff might not be there. Don't buy GENTING just because it owned 20% of TauRx ... Buy GENTING for other reasons.
We are Taurx shareholders for a long time n we know the privately done transacted market prices. Was usd150/share 3 months ago, now at minimum usd200/share after NfL data. Buyers are expecting this NfL data to substantially improve our chance of securing FDA AA (see Tofersen's case link) + more upside next year during China deal. --------------------------
Thanks. Where/how are these private transactions reported to TauRx shareholders? When was the last transaction, price, number of shares?
“From other channel checks, we understand that TauRx shares are now transacting at a much higher US$200-US$300 each. We are told that since not all shareholders participated in the aforementioned rights issue and thus, did not receive the warrants, Genting may effectively get to raise its shareholding in TauRx from 20% for cheap,” it said.
Thanks that is helpful data. Dundee Corp on the Toronto Stock Exchange (TSX: DC.A) owns 3.2% of TauRx. If the USD$200 price is real, Dundee's investment in TauRx is worth 3x Dundee's current market cap. Dundee is currently carrying it's TauRx investment at US$45 they hold just over 1M TauRx shares.
Dundee owned and controlled by Jews with unfair ordinary shares voting rights (100:1). Ordinary shares kena "poisoned". Preference shareholders making profit, ordinary shareholders suffer. Becareful when you buy such stocks.
From what I can see preference shares don't have any priority over ordinary shares in a liquidation/sale event and convert to ordinary shares on large financings or regulatory approvals (which is what matters). Here's some disclosure from Dundee...
In order to fund the new study and bolster its cash reserves, TauRx negotiated an investment from an existing shareholder through the issuance of a new class of preference shares in the company. The investor subscribed for 500,000 class B preference shares at an aggregate subscription amount of US$100 million or US$200/share. The new class of preference shares does not have any liquidation preferences but conveys to the holder a call option to acquire commercialization rights for LMTX® over certain territories in Asia. The preference shares are convertible to ordinary shares on a one-to-one basis upon the attainment of pre-specified regulatory and/or listing objectives alongside the injection of a further material amount of cash. The investment was made in three tranches with the initial tranche (350,000 shares/US$70 million) completed in January 2020, and the final two tranches (totalling 150,000 shares/US$30 million) completed in August 2020. TauRx is actively engaged in negotiating commercialization rights with partners in other territories. In June 2020, TauRx announced that it had signed a term sheet with Mediforum Pharmaceutical Co. Ltd (“Mediforum”), giving the Kosdaq-listed company rights to acquire publishing, manufacturing and intellectual property rights in Korea for LMTX®. In October 2020 and as part of the deal terms, Mediforum acquired 25,000 shares of TauRx for US$5 million.
@Marginofsatefy, u just joined tis forum on 16 Aug 2023 (yesterday) and is already so resourceful abt TauRx. U hv put many to shame w yr knowledge. U shud b here years ago when TauRx was born.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
troy88
3,110 posts
Posted by troy88 > 2023-08-16 10:38 | Report Abuse
Coming!